Changes in the use patterns of bDMARDs in patients with rheumatic diseases over the past 13 years
| Autor: | Federico Díaz-González, Manuel José Moreno-Ramos, Yanira Perez-Vera, Diana Sueiro-Delgado, Águeda Prior-Español, Enrique González-Dávila, Fernando Sánchez-Alonso, Raquel Martín-Domenech, Paloma Vela-Casasempere, Jerusalen Calvo-Gutiérrez, Blanca Garcia-Magallon, Dolores Ruiz-Montesino, Lorena Expósito, Javier García-González, Carlos Sánchez-Piedra, Inmaculada Ros-Vilamajo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.medical_specialty Science Charlson index Article Arthritis Rheumatoid Disease activity 03 medical and health sciences Psoriatic arthritis Rheumatic diseases Medical research 0302 clinical medicine Time frame Rheumatology Rheumatic Diseases Internal medicine medicine Humans Spondylitis Ankylosing In patient Registries 030212 general & internal medicine Biosimilar Pharmaceuticals 030203 arthritis & rheumatology Ankylosing spondylitis Multidisciplinary business.industry Arthritis Psoriatic Middle Aged Retention rate medicine.disease Spain Antirheumatic Agents Rheumatoid arthritis Medicine Female Tumor Necrosis Factor Inhibitors business |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-021-94504-x |
| Popis: | The better understanding of the safety of biologic DMARDs (bDMARDs), as well as the emergence of new bDMARDs against different therapeutic targets and biosimilars have likely influenced the use patterns of these compounds over time. The aim of this study is to assess changes in demographic characteristics, disease activity and treatment patterns in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) who started a first- or second-line biologic between 2007 and mid-2020. Patients diagnosed with RA, PsA or AS included in the BIOBADASER registry from January 2007 to July 2020 were included. According to the start date of a first- or second-line biologic therapy, patients were stratified into four time periods: 2007–2009; 2010–2013; 2014–2017; 2018–2020 and analyzed cross-sectionally in each period. Demographic and clinical variables, as well as the type of biologic used, were assessed. Generalized linear models were applied to study the evolution of the variables of interest over time periods, the diagnosis, and the interactions between them. A total of 4543 patients initiated a first biologic during the entire time frame of the study. Over the four time periods, disease evolution at the time of biologic initiation (p p p p p p p p p = 0.004), and incremental changes to the therapeutic target between the first and second biologic (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink